drugset
drugset / Trial / NCT00696332

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

NCT00696332 ↗

Phase 2 Completed 559 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy, tolerability and safety of oral administration of talampanel compared to a placebo in subjects with ALS.

Timeline

Start
2008-09
Primary completion
2010-04
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Talampanel Small molecule 25 mg Oral
Subject Talampanel Small molecule 50 mg Oral

Indications

amyotrophic lateral sclerosis